MedLumics Successfully Completes FIM Study for AblaView Technology
MedLumics announced the significant milestone of completing its First in Man (FIM) study for the AblaView® Optically Guided Pulsed Field Ablation (PFA) system. This innovative system showcases its efficacy in treating atrial fibrillation (AF), which remains one of the most prevalent heart arrhythmias impacting millions globally. The study's completion underscores MedLumics' commitment to enhancing AF treatment through advanced technology.
Overview of the Key Findings
The findings from this clinical investigation will be shared at the upcoming AF Symposium 2025 by Dr. Atul Verma of McGill University. This presentation will occur during the Late-Breaking Clinical Science session, reflecting on the real-time capabilities of the AblaView system in monitoring and ensuring successful treatments for patients suffering from AF.
Expert Leadership and Institutional Collaboration
The study was conducted at a leading hospital with a team of experts guiding the process. Notable figures such as Dr. Atul Verma and Prof. Raphael Martins led the clinical activities, ensuring a comprehensive and robust study adherence. Their leadership signifies the quality-driven approach MedLumics practices in research and development.
Significance of the AblaView System in AF Treatment
Atrial fibrillation affects an estimated 100 million people worldwide and its prevalence is rising, primarily due to the aging population. Recognizing the growing challenge associated with AF management, MedLumics has developed AblaView, a catheter-based PFA technology. This system uses Optical Coherence Reflectometry (OCR) to guide treatment and enhance the effectiveness of lesion creation, a critical factor in reducing recurrence rates in ablation procedures.
Clinical Implications and Future Applications
The AblaView system allows clinicians to assess lesion formation and durability in real time, promoting more effective treatment strategies. With a proprietary multibeam technology, it offers precise monitoring capability that can help optimize atrial fibrillation treatment procedures while aiming to minimize complications and enhance overall patient safety. MedLumics is dedicated not just to atrial fibrillation but also aims to diversify its applications within the medical field.
About MedLumics
Established in 2014, MedLumics has earned ISO13485 and ISO9001 certifications, reflecting its commitment to quality and safety in medical device manufacturing. With a foundation based on innovation, the company integrates optical and electrical components, providing comprehensive solutions for better health outcomes.
MedLumics is also actively engaged with various funding bodies, exemplifying its potential and reliability in the medical device industry. Patients suffering from atrial fibrillation can look forward to promising advancements with MedLumics at the forefront of technology development in this sector.
Frequently Asked Questions
What is the AblaView® system?
The AblaView® system is a PFA technology designed to assist in catheter-based treatments for atrial fibrillation, providing real-time monitoring during ablation procedures.
Who presented the findings from the FIM study?
Dr. Atul Verma from McGill University will be presenting the study results at the AF Symposium 2025.
How does the AblaView system improve ablation procedures?
It offers real-time verification of catheter contact and lesion durability, which can lead to better outcomes and reduced recurrence rates.
What is MedLumics' mission?
MedLumics focuses on innovating and optimizing medical devices to improve patient outcomes, especially in atrial fibrillation treatments.
When will the AblaView system be available for commercial use?
The AblaView® system is currently investigational and not available for commercial use yet but shows great potential in clinical trials.
